# Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19.

> **NCT04952805** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Toscana Life Sciences Sviluppo s.r.l.** · enrollment: 800 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** MAD0004J08
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04952805
- **Lead sponsor:** Toscana Life Sciences Sviluppo s.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-06
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2022-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952805, "Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04952805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*